Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Profit After Tax (2019 - 2026)

Revolution Medicines has reported Profit After Tax over the past 7 years, most recently at -$364.9 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 87.54% year-over-year to -$364.9 million; the TTM value through Dec 2025 reached -$1.1 billion, down 88.52%, while the annual FY2025 figure was -$1.1 billion, 88.52% down from the prior year.
  • Profit After Tax for Q4 2025 was -$364.9 million at Revolution Medicines, down from -$305.2 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$37.2 million in Q1 2021 and troughed at -$364.9 million in Q4 2025.
  • A 5-year average of -$130.2 million and a median of -$103.4 million in 2023 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: decreased 7.27% in 2022 and later plummeted 185.87% in 2023.
  • Year by year, Profit After Tax stood at -$52.7 million in 2021, then dropped by 7.27% to -$56.5 million in 2022, then crashed by 185.87% to -$161.5 million in 2023, then decreased by 20.45% to -$194.6 million in 2024, then plummeted by 87.54% to -$364.9 million in 2025.
  • Business Quant data shows Profit After Tax for RVMD at -$364.9 million in Q4 2025, -$305.2 million in Q3 2025, and -$247.8 million in Q2 2025.